Dr Robert Hess: Corona drug molnupiravir significantly reduces number of severe cases of disease and raises hopes, says manufacturer. Merck Sharp and Dohme (MSD), the US pharmaceutical giant based in Kenilworth, New York, last week reported positive results from a Phase III trial of its new corona drug, molnupiravir. The manufacturer claim that it alleviates…
Read More
Dr Robert Hess: FDA approves booster dose of Pfizer-BioNTech vaccine for the over-65s and for vulnerable categories but not yet for the wider population. The issue of booster vaccination has risen high on the agenda, and every country is taking a different approach to it. Israel, Austria and Russia are already offering booster jabs to…
Read More
Dr Robert Hess: A first step in the right direction: BioNTech introduces the “individualization” concept into vaccination strategy. Where are we now, almost two years into the pandemic? Nine months after the first vaccines for the prevention of Covid-19 were approved, are there any conclusions that can be reliably drawn? Since December 2020, 2.39 billion…
Read More
Dr Robert Hess: Current status and news of new concepts such as antibody therapy and vaccination by inhalation against COVID-19 infection. Dr Robert Hess has a special interest in this topic, because for some of our premium members the conventional vaccination against Covid-19 is not an option or even can be counterproductive. We see these…
Read More
Dr Robert Hess: Update on new mutations and what you need to know about COVID-19 variants. As experts in the field of human and molecular genetics and thus also on the topic of mutations, we provide regular updates and forecasts of where the pandemic might be heading. Recently, new discoveries have come into the frame,…
Read More
Dr Robert Hess: Second attempt for CureVac: Modified vaccine developed in collaboration with GSK is in preclinical testing. CureVac’s first-generation vaccine candidate CVnCoV unfortunately fell by the wayside in mid-June after failing to meet the statistical criteria for success, but there is now news regarding a modified second-generation vaccine candidate, which CureVac has developed in…
Read More
Dr Robert Hess: Recent studies have established a strong link between the presence of autoantibodies against interferon-I and a severe progression of disease after infection with SARS-CoV-2. As we have explained in previous Keynotes, our body’s own interferon system plays an important role in the activation and modulation of the immune defenses. In this update,…
Read More
Dr Robert Hess: FDA grants full approval to the Pfizer/BioNTech COVID-19 vaccine – What exactly does full FDA approval of a vaccine mean? The Pfizer/BioNTech COVID-19 vaccine first received Emergency Use Authorization (EUA) from the U.S. authorities in mid-December 2020 for administration to persons aged 16 and older. On Monday, the FDA announced that it…
Read More
Dr Robert Hess: Any decision on whether to receive a booster jab (and which one to choose) or to wait for a next-generation vaccine should be based on the following criteria. 1 – Which is preferable – a booster jab or a next-generation vaccine? This depends on a number of factors, primarily which next-generation vaccine…
Read More
As Dr Robert Hess expected, the pandemic is becoming more complex and problematic in nature, which makes it all the more difficult to make any firm predictions for the autumn. In focus: Vaccine side-effects versus post-acute sequelae (“Long Covid”). The forecast of Dr Robert Hess in the spring of 2021 that the pandemic would take…
Read More